The FDA rejected Aldeyra’s resubmission for reproxalap, citing efficacy concerns. The company plans another trial and aims to resubmit the NDA by mid-2025.
FDA Rejects Aldeyra’s Reproxalap For Dry Eye Disease Again, Citing Efficacy Concerns
Where Today's News Shapes Tomorrow
